At NextGen Life Science Automation, Festo is researching new solutions for medical technology and laboratory automation. At Hannover Messe 2026, Festo and Fraunhofer IPA will be demonstrating the construction of a cassette for the process step of modifying cells in CAR-T cell therapy. Automation significantly reduces production times and costs, making customised cancer therapies faster, cheaper and available to more patients.

Festo, one of the world's leading manufacturers of automation technology, is fully integrating Eichenberger Gewinde AG from Burg in Switzerland as of 1 April 2026. In future, the Swiss company will operate under the name "Festo Gewindetriebe AG".

Bioprocesses are becoming increasingly important for industry, as they represent sustainable alternatives to conventional production processes and enable the manufacture of new products. With BioTech Automation, Festo is presenting an overview of already available components and solutions at Analytica based on selected cultivation processes, which will be demonstrated in three bioreactors: a loop bioreactor, a stainless steel reactor and a benchtop laboratory reactor.

"Seamless Automation combines our broad-based solution portfolio with end-to-end connectivity and an intuitive digital experience for our customers," explains Frank Notz, Chief Sales Officer at Festo. Visitors can immerse themselves in the world of seamless automation at the Festo stand in Hall 13 at the Hannover Messe.